

SUBJECT INDEX VOLUME 20

A

ACTH, 177, 434, 628
 Activation study, 565
 Addiction, 297
 Adenosine A₁ receptor, 271
 Adenosine A_{2A} receptor, 44
 Adenyl cyclase, 612
 α₂-Adrenoceptors, 460
 Affective disorders, 271
 Aggression, 413
 α₂-agonist, 357
 Alcoholism, 640
 Alpha₂-adrenergic receptors, 162
 alpha₂-Adrenoceptors, 119
 Alzheimer's disease, 357
 Amphetamine, 35, 322, 533, 591
 Amphetamine sensitization, 248
 Amygdala, 582
 Animal model, 10, 542
 Anti-serotonin antibodies, 386
 Antidepressants, 226, 370
 Antipsychotic, 44, 491, 612
 Antipsychotic drugs, 403
 Anxiety, 81, 162
 Anxiety disorders, 99
 Aripiprazole, 612
 Associative learning, 533
 Atropine, 263
 Attentional set-shifting, 460
 AVP, 434

B

Behavioral sensitization, 10
 Benzodiazepine, 255
 Benzodiazepine receptors, 650
 Bipolar disorder, 380
 Brofaromine, 226

C

C-6 cells, 612
 Ca²⁺ channel, 248
 Candidate genes, 640
 Carbamazepine, 271
 Catecholamine, 29, 201, 603
 CCK, 141
 Chinese hamster ovary cells, 263
 CHO cells, 612
 Cholecystokinin, 81
 Cholecystokinin tetrapeptide (CCK-4), 177
 Cholinergic, 434
 Cholinesterase inhibitor, 357
 Chronic treatment, 271
 Cigarettes, 392
 Citalopram, 287
 Clonidine, 119
 Clozapine, 29, 44, 263, 340
 Cocaine, 297, 542, 556, 582, 591
 Cognition, 106, 201
 Cognitive functions, 119
 Combinatorial chemistry, 99

Conditioned place preference, 591
 Conditioned stimuli, 542
 Conditioning, 533, 591
 Context, 533
 Contingency, 542
 Corticosterone, 248
 Cortisol, 177, 434, 628
 Coupling, 162
 Craving, 297, 471, 542
 CSF, 517
 Cytochromes P-450, 480
 Cytokines, 370

D

D₂ receptor, 424
 Decision making, 322
 Depression, 99, 162, 188, 370, 447, 491
 Discriminative stimulus, 471
 Dizocilpine, 311
 Dopamine, 141, 201, 287, 424, 517
 Dopamine D₁ antagonists, 35
 Dopamine D₂ antagonists, 35
 Dopamine D₂ receptor, 60
 Dopamine D₃ receptor, 60
 Dopamine receptors, 248, 612
 Dopamine restitutive system, 365
 DRD2, 640
 Drug-seeking, 542
 Drug-seeking behavior, 591
 Drug-taking, 542
 Dyskinesia, 35
 Dystonia, 35

E

Early-genes, 44
 Ecstasy, 565
 Environment, 533
 Ethanol, 279, 471
 Euphoria, 582
 Exercise, 150
 Expectation, 542
 Extracellular glutamate levels, 346
 Extrapyramidal side effects, 35

F

FDG-PET, 565
 Fluoxetine, 447, 628
 Fluphenazine, 29
 Fos, 92
 Fos-like-immunoreactivity, 44
 Frontal functions, 357
 Functional selectivity, 612

G

G Protein, 162
 GABA, 92
 GABA_A agonist, 346

GABA_A antagonist, 346
 GABA_A receptors, 255
 Gastrin-releasing peptide, 52
 Genetic association, 640
 Genomics, 99
 Glucose metabolic rate, 413
 Glutamate, 106, 201, 311
 Growth hormone, 177, 628
 [³⁵S] GTPγS binding, 263
 Guanfacine, 119

H

Haloperidol, 44, 403
 Haplotypes, 640
 High-throughout screening, 99
 Hippocampus, 287, 582
 Homovanillic acid, 603
 5-HT, 322
 5-HT_{2B}, 556
 5-HT_{2C}, 556
 5-HT_{1A} receptor, 424, 628
 5-HT_{2A} receptor, 424
 Human, 424, 460
 Human brain, 60
 Human muscarinic receptor subtypes, 263
 Hyperactivity, 556
 Hypnotic use, 279

I

Ibotenic acid, 525
 Immobilization stress, 248
 In vivo binding, 255
 In vivo microdialysis, 287
 Indoleamine hallucinogen, 424
 Insomnia, 279
 Interferon-γ, 370
 Interleukin-10, 370
 Interneuron, 92
 [¹²³I]iomazenil, 650
 Ipsapirone, 150, 628

K

Ketamine, 106, 201
 Kraepelin test, 365

L

Latent inhibition, 525
 Learning and memory, 119
 Lithium, 380
 Locomotion, 591
 Locomotor activity, 533

M

M100907, 311
 Magnetic resonance imaging, 413

MAOIs, 226
 Marathon running, 150
 m-chloro-phenylpiperazine (mCPP), 287
 MDE, 565
 Mecamylamine, 297
 Medial preoptic area, 346
 Memory, 106, 201
 Mental stress, 365
 Meta-chlorophenylpiperazine (m-CCP), 150
 Methamphetamine, 565
 Microdialysis, 92, 403
 Moclobemide, 226
 Model psychosis, 424, 565
 Monkeys, 35
 Monoamine oxidase, 392
 Mood effects, 279
 MRI, 582
 mRNA expression, 271

N

Naltrexone, 471
 Negative symptoms, 491
 Neuroendocrine cells, 52
 Neuropeptide Y, 177
 Nicotine, 52, 297
 Nicotinic receptors, 52
 Nifedipine, 248
 NMDA, 106
 Nonisotopic in situ hybridization, 60
 Noradrenaline, 119
 Norepinephrine, 29, 188, 517
 Novelty, 533
 Nucleus accumbens, 287

O

Ondansetron, 177
 Opiates, 322
 Orbital cortex, 413
 Orbital prefrontal cortex, 322

P

Panic, 81
 Panic disorder, 162, 177, 386
 PET, 582
 Phencyclidine, 201
 pHVA, 365

Physostigmine, 434
 Pindolol, 380
 Planning, 460
 Plasma homovanillic acid, 365
 Positron emission tomography (PET), 340, 424
 Post-traumatic stress disorder, 188
 Posterior hypothalamus, 346
 Postnatal hippocampal lesion, 525
 Prefrontal cortex, 92, 201
 Premenstrual, 81
 Prepulse inhibition, 141, 311
 Primates, 10, 517
 Priming, 542
 Prolactin, 177, 413
 Promoter, 640
 Proton magnetic resonance spectroscopy, 131
 Psilocybin, 424, 565
 Psychomotor stimulant, 542
 Psychopathology, 424
 Psychosis, 603
 Psychotomimetic, 201
 Pulmonary inflammation, 52

R

Raclopride, 340
 [¹¹C]raclopride, 424
 Rat, 287, 311, 471, 525, 533, 542
 Rearing behavior, 533
 Receptor binding, 60, 263
 Relapse, 471
 REM sleep, 447
 RIMAs, 226
 Risperidone, 340
 Ro 15-1788, 255

S

SB 206553, 556
 Schizophrenia, 10, 29, 92, 99, 106, 131, 141, 201, 311, 340, 365, 392, 403, 424, 491, 525, 603, 612, 650
 Schizophrenia-markers, 392
 Second messengers, 263
 Second-order schedule, 542
 Selective serotonin reuptake inhibitors, 480
 Selegiline, 582
 Self-administration, 279, 471, 542

Semantic priming, 357
 Sensitization, 533
 Sensorimotor gating, 141
 Serotonin, 92, 150, 188, 287, 311, 386, 413, 424, 517, 556
 Serotonin anti-idiotypic antibodies, 386
 Serotonin receptors, 386
 Sex differences, 10, 434
 Shuttle box, 525
 Signal transduction, 271
 Single nucleotide polymorphisms, 99
 Sleep deprivation, 380
 Sleep EEG, 447
 Smoking, 392
 Specific serotonin reuptake inhibitors (SSRIs), 628
 SPECT, 650
 Spillover, 29
 Startle, 311
 Stereotypy, 591
 Stimulants, 10
 Strain, 311
 Stress, 533
 Striatum, 287, 403, 424
 Substance dependence, 640

T

TaqI "A" system, 640
 Tobacco, 52
 Tolerability, 491
 Tryptophan, 188
 Tyrosine, 188

V

Venlafaxine, 480
 Vigilance, 346

W

Women, 81
 Working memory, 460

Z

Ziprasidone, 491